Asklepios Klinik Gauting GmbH

At Asklepios Klinik Gauting GmbH, most clinical trials focus on neoplasms, especially non-small cell lung cancer and small-cell lung cancer. The research is centered on testing new treatment strategies, improving outcomes in advanced disease, and matching therapies to specific tumor features.

• Studies in advanced, metastatic, and resectable NSCLC
• Research in SCLC and large-cell neuroendocrine carcinoma
• Trials using biomarker-guided and targeted approaches for lung cancer

This work reflects a strong emphasis on evaluating whether newer cancer therapies can extend survival, delay progression, and improve care for patients with difficult-to-treat lung tumors.

The site conducts many studies in oncology that explore immune-based and molecularly targeted treatments for lung cancer. These trials aim to determine whether newer combinations can outperform standard treatment and better control disease in patients with specific genetic or protein markers.

• Trials for EGFR-mutated, RET fusion-positive, KRAS G12C, and MET-driven tumors
• Studies of PD-L1-selected and biomarker-defined populations
• Comparisons of novel antibodies, antibody-drug conjugates, and checkpoint-based regimens

These investigations are designed to refine treatment selection and test whether personalized cancer therapy can improve survival and response rates.

Beyond cancer care, the research portfolio includes respiratory tract diseases such as idiopathic pulmonary fibrosis, bronchiectasis, COPD, and pulmonary hypertension associated with interstitial lung disease. The main purpose is to assess whether new therapies can improve breathing, preserve lung function, and reduce symptom burden.

• Studies focused on fibrotic lung disease and lung function decline
• Trials in bronchiectasis aiming to lower exacerbations and respiratory symptoms
• Research in COPD and other chronic pulmonary conditions

This area shows a clear interest in supportive and disease-modifying approaches for patients living with long-term lung disorders.

The clinical trial program also covers bacterial infections and mycoses, with studies in nontuberculous mycobacterial lung infection and chronic pulmonary aspergillosis. These trials are aimed at improving treatment options for infections that are often persistent and difficult to manage.

• Research in NTM lung infection caused by Mycobacterium avium complex
• Studies of chronic pulmonary aspergillosis in patients with limited options
• Evaluation of therapies intended to improve symptoms and clinical response

The work in this field supports better infection control and more effective care for patients with complex chronic lung infections.

Some trials at the site also reflect broader research in cell physiological phenomena and environment and public health, often through biomarker-driven studies and disease monitoring tools. These efforts are intended to improve diagnosis, guide treatment decisions, and deepen understanding of how disease behaves over time.

• Use of molecular markers to refine cancer prognosis and treatment planning
• Studies that examine disease activity and response through biomarker-based approaches
• Research supporting earlier identification of patients who may benefit from treatment intensification

At Onkologisches Studienzentrum, this translational focus complements the larger oncology program by linking laboratory insights with practical patient care.